Search
Crisugabalin
go.drugbank.com/drugs/DB19300InvestigationalCrisugabalin is under investigation in clinical trial NCT06490484 (Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to
Tulisokibart
go.drugbank.com/drugs/DB18719InvestigationalPRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known as tumour necrosis factor (TNF)-like ligand 1A (TL1A) and TNF superfamily member 15. … It is being investigated for ulcerative colitis.
GsMtx-4
go.drugbank.com/drugs/DB17861InvestigationalGsMtx-4 is a peptide found in tarantula venom that inhibits mechanosensitive ion channel (MSC) activity.
MCMV5322A
go.drugbank.com/drugs/DB17763InvestigationalMCMV5322A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with [MCMV3068A] to form RG7667.[A259362]
MCMV3068A
go.drugbank.com/drugs/DB17764InvestigationalMCMV3068A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with [MCMV5322A] to form RG7667.[A259362]
Iproniazid
go.drugbank.com/drugs/DB04818ApprovedWithdrawnWithdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesDCLL-9718S
go.drugbank.com/drugs/DB17392InvestigationalDCLL9718S is under investigation in clinical trial NCT03298516 (A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine … in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy).
Ravagalimab
go.drugbank.com/drugs/DB16676InvestigationalRavagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe It Is in Participants With Moderate to Severe Ulcerative Colitis
V-SARS
go.drugbank.com/drugs/DB15812InvestigationalImmunitor Inc., the sponsor, is currently testing this oral vaccine for immunogenicity in 20 healthy volunteers in a Phase 1 clinical trial (NCT04380532). … This therapeutic concept was applied to the development of V-SARS, which heat inactivates the plasma, and packages it into a once-daily pill form.